Bivigam IGIV

Generic name: Immune Globulin Intravenous (human) 10%
Dosage form: injection for intravenous infusion
Drug class: Immune globulins

Usage of Bivigam IGIV

Bivigam is a 10% solution of Human Immune Globulin (IVIG) that is given by intravenous infusion (an injection into a vein) by a healthcare provider to treat adults and children aged 2 years of age and older with primary humoral immunodeficiency – which is an immune system that does not work correctly.

Primary humoral immunodeficiencies are characterized by defects in B lymphocytes – these are key players in our immune response. B cell abnormalities in primary humoral immunodeficiency classically result in decreased B cell numbers, impaired antibody production, or both, leading to an increased risk of infection, including severe infections.

Bivigam works by replacing missing immune globulin in people with primary humoral immunodeficiency, although the exact way it works is not understood.

Bivigam was FDA approved on December 20, 2012.

Bivigam IGIV side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your caregiver if you feel dizzy, nauseated, light-headed, sweaty, or have a headache, pounding in your neck or ears, fever, chills, chest tightness, or warmth or redness in your face.

Bivigam may cause serious side effects. Call your doctor at once if you have:

signs of a blood cell disorder--pale or yellowed skin, dark colored urine, fever, confusion or weakness symptoms of dehydration --feeling very thirsty or hot, being unable to urinate, heavy sweating, or hot and dry skin kidney problems--little or no urination, swelling, rapid weight gain, feeling short of breath lung problems--chest pain, trouble breathing, blue-colored lips, fingers, or toes signs of a new infection--fever with a severe headache, neck stiffness, eye pain, and increased sensitivity to light or signs of a blood clot--shortness of breath, chest pain with deep breathing, rapid heart rate, numbness or weakness on one side of the body, swelling, and warmth or discoloration in an arm or leg.

Common side effects of Bivigam affecting 5% or more people may include:

headache

fatigue

infusion site reactions (pain, swelling, burning, or irritation where the IV needle was inserted)

nausea

sinusitis (stuffy nose, sinus pain)

increased blood pressure

diarrhea

dizziness

lack of energy.

Other reported side effects include:

back pain, joint pain

fever, chills, sweating, warmth or tingling

stomach pain

fast heartbeats.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before taking Bivigam IGIV

You may not be able to use this medicine if:

you have had an allergic reaction to an immune globulin or blood product you have immune globulin A (IgA) deficiency with antibodies to IgA.

Bivigam can cause blood clots or kidney problems, especially in older adults or in people with certain conditions. Tell your doctor if you have ever had:

heart problems, blood circulation problems, or "thick blood"

a stroke or blood clot

kidney disease

diabetes

an infection called sepsis

if you use estrogens (birth control pills or hormone replacement therapy)

if you have been on long-term bedrest or

if you have a central intravenous (IV) catheter in place

you are over the age of 65

you are pregnant or intend to become pregnant

you are breastfeeding.

Pregnancy and breastfeeding

The use of Bivigam in pregnant women has not been evaluated and it should be used only if needed. It is not known if it can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Immune globulins cross the placenta from maternal circulation increasingly after 30 weeks of gestation.

No human data are available about the use of Bivigam in breastfeeding women. Talk to your healthcare provider about the risks.

Relate drugs

How to use Bivigam IGIV

Bivigam is given as a slow infusion into a vein, usually once every 3 to 4 weeks. A healthcare provider will give you this injection.

Drink plenty of liquids while you are using Bivigam to help improve your blood flow and keep your kidneys working properly.

You may need frequent blood or urine tests.

This medicine can affect the results of certain medical tests. Tell any doctor who treats you that you are using IGIV.

Warnings

May cause hypersensitivity reactions. Do not use in people with a history of anaphylactic or severe systemic reactions to human immunoglobulin or in IgA deficient patients with antibodies to IgA and a history of hypersensitivity.

Bivigam can cause blood clots. The risk is highest in older adults or in people who have had blood clots, heart problems, or blood circulation problems. Blood clots are also more likely during long-term bedrest, while using birth control pills or hormone replacement therapy, or while having a central intravenous (IV) catheter in place. Call your doctor at once if you have chest pain, trouble breathing, fast heartbeats, numbness or weakness, or swelling and warmth or discoloration in an arm or leg.

This medicine can also harm your kidneys, especially if you have kidney disease or you also use certain medicines. Tell your doctor right away if you have signs of kidney problems, such as swelling, rapid weight gain, and little or no urination.

Aseptic meningitis syndrome (inflammation of the lining of the brain) may occur rarely with infrequently with IGIV treatments including Bivigam. It usually begins within several hours to 2 days following IGIV treatment. Call your healthcare provider at once if you develop a severe headache, neck stiffness, drowsiness, fever, sensitivity to light, painful eye movements, nausea, or vomiting.

Hemolysis (a breakdown in red blood cells) and delayed hemolytic anemia can develop following IGIV therapy (including Bivigam). Call your healthcare provider at once if you develop fatigue, increased heart rate, yellowing of skin or eyes, or dark-colored urine.

Fluid in the lungs (noncardiogenic pulmonary edema) related to the infusion (transfusion-related acute lung injury [TRALI]) has been reported following IVIG infusions, typically within 1 to 6 hours of treatment. Tell your doctor immediately if you have difficulty breathing, chest pain, blue lips or extremities, or develop a fever.

Immune globulin is made from donated human plasma and may contain viruses or other infectious agents. Donated plasma is tested and treated to reduce the risk of contamination, but there is still a small possibility it could transmit disease. Ask your doctor about any possible risks.

What other drugs will affect Bivigam IGIV

Bivigam can harm your kidneys, especially if you also use certain medicines for infections, cancer, osteoporosis, organ transplant rejection, bowel disorders, high blood pressure, or pain or arthritis (including Advil, Motrin, and Aleve).

Bivigam may have a short-term effect on your immune response to live virus vaccines, such as measles, mumps, rubella, and varicella. Talk to your doctor about the best time to be immunized.

May also interfere with the results of certain laboratory tests.

Other drugs may affect Bivigam, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.